Detecting Methylation in Serum for Gastric Cancer Diagnosis
Author Information
Author(s): Leung W K, To K-F, Chu E S H, Chan M W Y, Bai A H C, Ng E K W, Chan F K L, Sung J J Y
Primary Institution: The Chinese University of Hong Kong
Hypothesis
Can detecting promoter hypermethylation in the serum of gastric cancer patients provide diagnostic and prognostic value?
Conclusion
The study found that detecting DNA methylation in the serum may help diagnose and predict outcomes in gastric cancer patients.
Supporting Evidence
- 55% of gastric cancer patients had methylation detected in the serum.
- Methylation of APC and E-cadherin was associated with worse prognosis.
- Specificity of the methylation markers was 86%.
Takeaway
Doctors can check for certain changes in the blood of stomach cancer patients to help figure out how serious their cancer is and how to treat it.
Methodology
DNA was extracted from serum samples of gastric cancer patients and controls, and methylation was analyzed using quantitative PCR.
Potential Biases
Potential bias in patient selection and the specificity of the methylation markers used.
Limitations
The study had a relatively small sample size and focused only on specific methylation markers.
Participant Demographics
60 Chinese patients with confirmed gastric adenocarcinoma (58.3% male, mean age 66 years).
Statistical Information
P-Value
P=0.006
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website